Essentials of Oncothermia

Table 4

Summary of the studies made by oncothermia treatment. (end points are response connected.)

Study	Number of patients	Complete remission (CR) [%]	Partial remission (PR) [%]	No change (NC), stable disease (SD) [%]	Overall response rate (CR + PR + SD) [%]	Reference
Colorectal inoperable, liver metastasis	60
CDDP	28	0	3.57	3.57	7.14	[108]
OXALI	32	0	15.63	15.63	31.25
Ovary (relapsed, advanced epithelial)	26					[87]
Heavily pretreated	13	0.00	23.08	38.46	61.54
Not heavily pretreated	13	30.77	23.08	38.46	92.31
General oncology	277		21.50	37.00	58.50	[109]
TCM general oncology	306
Oncothermia + TCM	75	6.67	57.33	26.67	90.67	[110]
Oncothermia + TCM + i.v.CTx	65
Passive arm	51	7.84	60.78	15.69	84.31	[110]
Active arm	14	14.29	64.28	21.43	100.00
Oncothermia + TCM + abdominal perfusion	87				0.00
Passive arm	45	2.22	40	24.44	66.66	[110]
Active arm	42	7.14	54.76	26.19	88.09
Oncothermia + TCM + bladder perfusion	37
Passive arm	24	0	50	12.5	62.50	[110]
Active arm	13	7.69	53.85	30.77	92.31
Oncothermia + TCM + RTx	42
Passive arm	30	3.33	50	16.67	70.00	[110]
Active arm	12	8.33	66.67	16.67	91.67
Abdominal effusion + oncothermia	49	4.08	53.06	16.38	73.52	[110]
Chronic pelvic inflammation	283					[111]
Passive arm	143
Active arm	140	46.10	29.40	19.60	95.10
Chronic bronchitis, TCM + oncothermia	35	30.00	24.30	25.70	80.00	[111]
Colon cancer study, phase II, prospective, three arms, randomized	154					[110]
Clifford TCM	53	5.7	28.3	18.9	52.90
Monotherapy	50	10	26	26	62.00
Combined therapy	51	13.7	45.1	23.5	82.30
Colon operability	7	71			71.00	[112]
Prostatitis	72					[111]
Passive arm	36	16.70	27.80	19.40	63.90
Active arm	36	41.70	36.10	22.20	100.00
Prostate study	184	49.5	15.2	15.8	80.50	[113]
Prostate cancer (Kleef) (Gleason Score 2–6)	16					[114]
Oncothermia + hormone therapy	8				50
Oncothermia monotherapy	8				37.5
Prostate cancer (Kleef) (Gleason Score 7–9)	17					[114]
Oncothermia + hormone therapy	11				81.82
Oncothermia monotherapy	6				33.33
Peyronie’s disease	25				100
Pancreas	42		23.8	31	54.80	[81]
Pancreas	30	3.3	33.3	40	76.60	[79, 80]
Esophagus		8	50	42	100.00	[72]
CRC liver	22	5		23	28	[76]
CRC liver	15		20	60	80.00	[75]
CRC liver oxalplatin	12				8.3	[77]
CRC liver cisplatin	18				27.8
Advancer liver	28					[67]
Oncothermia + RTx	16		31	50	81
Oncothermia + CTx	8		13	25	38
Oncothermia monotherapy	4			25	25
Brain	19		11	32	43	[57]
Asthma	7		75	10	85	[115]
Small-cell lung cancer (SCLC)	38		44.7	15.8	60.5	[116]
Benign tumors oncothermia + TCM	35	54.3	25.7		80.00	[111]